Ahmad A (2019) Breast cancer statistics: recent trends. Adv Exp Med Biol 1152:1–7. https://doi.org/10.1007/978-3-030-20301-6_1

Article  CAS  PubMed  Google Scholar 

Pedersen RN, Esen BO, Mellemkjaer L, Christiansen P, Ejlertsen B, Lash TL, Norgaard M, Cronin-Fenton D (2022) The incidence of breast cancer recurrence 10–32 years after primary diagnosis. J Natl Cancer Inst 114:391–399. https://doi.org/10.1093/jnci/djab202

Article  CAS  PubMed  Google Scholar 

Tewari A, Chagpar AB (2014) Worry about breast cancer recurrence: a population-based analysis. Am Surg 80:640–645

Article  PubMed  Google Scholar 

Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM, Wolff AC (2020) Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol 38:1346–1366. https://doi.org/10.1200/JCO.19.02309

Article  PubMed  Google Scholar 

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JM, Bilous M, Ellis IO, Fitzgibbons P, Hanna W (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. Arch Pathol Lab Med 142:1364–1382

Article  PubMed  Google Scholar 

Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18–43

Article  CAS  PubMed  Google Scholar 

Marchiò C, Annaratone L, Marques A, Casorzo L, Berrino E, Sapino A (2021) Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond. Semin Cancer Biol 72:123–135

Article  PubMed  Google Scholar 

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418–8423. https://doi.org/10.1073/pnas.0932692100

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hubay CA, Pearson OH, Marshall JS, Stellato TA, Rhodes RS, DeBanne SM, Rosenblatt J, Mansour EG, Hermann RE, Jones JC, Flynn WJ, Eckert C, McGuire WL (1981) Adjuvant therapy of stage II breast cancer: 48-month follow-up of a prospective randomized clinical trial. Breast Cancer Res Treat 1:77–82. https://doi.org/10.1007/BF01807895

Article  CAS  PubMed  Google Scholar 

Group EBCTC (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet 365:1687–1717

Article  Google Scholar 

Krishnamurti U, Silverman JF (2014) HER2 in breast cancer: a review and update. Adv Anat Pathol 21:100–107. https://doi.org/10.1097/PAP.0000000000000015

Article  CAS  PubMed  Google Scholar 

Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737–744. https://doi.org/10.1200/JCO.1996.14.3.737

Article  CAS  PubMed  Google Scholar 

Zhu X, Verma S (2015) Targeted therapy in her2-positive metastatic breast cancer: a review of the literature. Curr Oncol 22:S19-28. https://doi.org/10.3747/co.22.2363

Article  CAS  PubMed  PubMed Central  Google Scholar 

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

Article  CAS  PubMed  Google Scholar 

Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684. https://doi.org/10.1056/NEJMoa052122

Article  CAS  PubMed  Google Scholar 

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA, Investigators DE-BT (2022) Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 387:9–20. https://doi.org/10.1056/NEJMoa2203690

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reix N, Malina C, Chenard MP, Bellocq JP, Delpous S, Moliere S, Sevrin A, Neuberger K, Tomasetto C, Mathelin C (2016) A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression. Breast Cancer Res Treat 160:249–259. https://doi.org/10.1007/s10549-016-4000-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moreno-Aspitia A, Hillman DW, Dyar SH, Tenner KS, Gralow J, Kaufman PA, Davidson NE, Lafky JM, Reinholz MM, Lingle WL (2013) Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831. Cancer 119:2675–2682

Article  CAS  PubMed  Google Scholar 

Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG (2016) Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 34:1134

Article  CAS  PubMed  PubMed Central  Google Scholar 

Allison KH (2021) Prognostic and predictive parameters in breast pathology: a pathologist’s primer. Mod Pathol 34:94–106. https://doi.org/10.1038/s41379-020-00704-7

Article  PubMed  Google Scholar 

Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA (2014) New strategies for triple-negative breast cancer–deciphering the heterogeneity. Clin Cancer Res 20:782–790. https://doi.org/10.1158/1078-0432.CCR-13-0583

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O’Shaughnessy J, Investigators K (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382:810–821. https://doi.org/10.1056/NEJMoa1910549

Article  CAS  PubMed  Google Scholar 

Haffty BG, Harrold E, Khan AJ, Pathare P, Smith TE, Turner BC, Glazer PM, Ward B, Carter D, Matloff E, Bale AE, Alvarez-Franco M (2002) Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359:1471–1477. https://doi.org/10.1016/S0140-6736(02)08434-9

Article  PubMed  Google Scholar 

Geyer C Jr, Garber J, Gelber R, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G (2022) Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol 33:1250–1268

Article  CAS  PubMed  Google Scholar 

Yamauchi H, Toi M, Takayama S, Nakamura S, Takano T, Cui K, Campbell C, De Vos L, Geyer C, Tutt A (2023) Adjuvant olaparib in the subset of patients from Japan with BRCA1-or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial. Breast Cancer. https://doi.org/10.1007/s12282-023-01451-8

Article  PubMed  Google Scholar 

Duffy MJ, McDermott EW, Crown J (2017) Use of multiparameter tests for identifying women with early breast cancer who do not need adjuvant chemotherapy. Clin Chem 63:804–806

Article  CAS  PubMed  Google Scholar 

Nicolini A, Ferrari P, Duffy MJ (2018) Prognostic and predictive biomarkers in breast cancer: past, present and future. Semin Cancer Biol 52:56–73

Article  CAS  PubMed  Google Scholar 

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726–3734. https://doi.org/10.1200/JCO.2005.04.7985

Article  CAS  PubMed  Google Scholar 

Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga JY, Bermejo B, Ramos-Vazquez M, Jung KH, Ferrero JM, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Pusztai L, Hortobagyi GN (2021) 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med 385:2336–2347. https://doi.org/10.1056/NEJMoa2108873

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW (2015) Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373:2005–2014. https://doi.org/10.1056/NEJMoa1510764

Article  CAS  PubMed  PubMed Central